Update on Peripheral T-Cell Lymphoma
Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.
Date: March 14, 2012
Time: 1:30 p.m. - 2:30 p.m. ET
Location: Telephone/Web
Target Audience: Oncology nurses and social workers interested in learning more about PTCL
Download: Program Slides
Listen: Presentation | Q&A Session
Access: Virtual lecture
Activity Purpose
To educate oncology nurses and social workers about updates in peripheral T-cell lymphoma (PTCL)
Educational Objectives
At the conclusion of this program, participants should be able to:
- Define PTCL
- Explain PTCL subtypes
- Discuss treatment options for patients with newly diagnosed and refractory or relapsed PTCL
- Discuss the role of clinical trials as treatment options for PTCL patients
- Identify PTCL information and support resources for patients, caregivers and healthcare professionals
Speaker
Steven M. Horwitz, MD
Assistant Attending, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY
Questions Asked by the PTCL Community
- Is there any relationship between sarcoidosis (an inflammatory disease) and PTCL? Is it possible to confuse the diagnoses?
- Is it true that how you feel after the first cycle of chemotherapy (what side effects you have) is how you will feel during the rest of cycles?
- With autologous transplant, is the survival rate now any better than it used to be?
- Are there any new drugs for PTCL on the horizon?
- If the disease comes back, is getting another biopsy necessary to understand how to best treat it?
- Is it true that young male patients treated for inflammatory bowel disease (IBD) are at risk of developing hepatosplenic T-cell lymphoma, and is it because of the treatment for IBD? And if so, how can that risk be reduced?
- What is the relationship between Epstein-Barr virus and PTCL?
- Can you explain the diagnosis of PTCL with a cytotoxic T-cell phenotype?
- Where does rituximab (Rituxan®) fit into PTCL treatment?
- What is the cure rate for stage IV lymphoblastic lymphoma? Are there any new drugs on the horizon?
- What would be the best treatment for pediatric ALK-positive anaplastic large cell lymphoma?
- What are the chances of relapse after being in remission following an autologous transplant?
Sponsors and Supporters
This program was sponsored by The Leukemia & Lymphoma Society and supported by grants from Allos Therapeutics and Celgene Corporation.
